Letter to Stockholders |
Business Events |
Financial Highlights
Pipeline Profile |
Marketed Product News |
Business Partner News
(in thousands, except per share amounts)
(unaudited)
|
Three Months
Ended March 31,
|
|
|
|
1997
|
1996
|
Revenues
|
Product sales
|
$154,213
|
$152,337
|
Royalties
|
65,312
|
52,893
|
Contract and other
|
21,409
|
22,100
|
Interest
|
16,351
|
15,554
|
Total revenues
|
257,285
|
242,884
|
|
|
|
Costs and expenses
|
Cost of sales
|
27,685
|
25,879
|
Research and development
|
122,743
|
115,633
|
Marketing, general and administrative
|
61,981
|
52,042
|
Interest
|
988
|
1,559
|
Total costs and expenses
|
213,397
|
195,113
|
|
|
|
Income before taxes
|
43,888
|
47,771
|
Income tax provision
|
12,289
|
9,554
|
|
|
|
Net income
|
$31,599
|
$38,217
|
|
|
|
Net income per share:
|
$0.25
|
$0.31
|
|
|
|
Weighted average shares used in computing per share amounts:
|
125,283
|
123,360
|
|
|
March 31,
|
|
1997
|
1996
|
Selected balance sheet data
|
Cash and short-term investments
|
$660,606
|
$761,149
|
Accounts receivable
|
205,561
|
174,865
|
Inventories
|
93,667
|
88,853
|
Long-term marketable securities
|
505,479
|
386,664
|
Property, plant and equipment, net
|
617,895
|
514,461
|
Other long-term assets
|
153,187
|
100,146
|
Total assets
|
2,282,166
|
2,065,668
|
Total current liabilities
|
248,464
|
224,377
|
Long-term debt
|
150,000
|
150,000
|
Total liabilities
|
422,351
|
400,356
|
Total stockholders' equity
|
1,859,815
|
1,665,312
|
|
The Press Release of Genentech's Second Quarter 1997 Results is also available.
|
